Vera Therapeutics director granted 17,084 stock options
Vera Therapeutics director Beth C. Seidenberg received a grant of stock options covering 17,084 shares of Class A common stock at an exercise price of $34.35 per share.
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Vera Therapeutics director Beth C. Seidenberg received a grant of stock options covering 17,084 shares of Class A common stock at an exercise price of $34.35 per share. The options vest in full on the earlier of the first anniversary of the grant date or the company’s 2027 annual stockholder meeting, provided she continues in service. They also fully vest if there is a change in control while she remains in service through that date.
Insider Trade Summary
Grant/Award: 17,084 shares
Grant/Award
1 txn
Insider
SEIDENBERG BETH C
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 17,084 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (right to buy) — 17,084 contracts (Direct)
Footnotes (1)
- F1. The shares subject to the option will vest in full on the earlier of the first anniversary of the grant date or the date of the Company's 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Notwithstanding the foregoing, the shares will vest in full upon a change in control, subject to the Reporting Person's continuous service through the date of such change in control.
Key Figures
Options granted: 17,084 options
Exercise price: $34.35 per share
Underlying shares: 17,084 shares
+2 more
5 metrics
Options granted
17,084 options
Stock Option (right to buy) granted to director
Exercise price
$34.35 per share
Exercise price for Class A common stock underlying options
Underlying shares
17,084 shares
Class A common stock underlying the option award
Expiration date
May 20, 2036
Option expiration for director grant
Post-grant derivative holdings
17,084 options
Total derivative securities following the reported transaction
Key Terms
Stock Option (right to buy), Class A Common Stock, exercise price, change in control, +1 more
5 terms
Stock Option (right to buy) financial
"security_title: Stock Option (right to buy)"
Class A Common Stock financial
"underlying_security_title: Class A Common Stock"
Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.
exercise price financial
"conversion_or_exercise_price: 34.3500"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
change in control financial
"shares will vest in full upon a change in control"
A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.
continuous service financial
"subject to the Reporting Person's continuous service through such vesting date"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Vera Therapeutics (VERA) director Beth Seidenberg report in this Form 4?
Beth C. Seidenberg reported receiving a stock option grant for 17,084 shares of Vera Therapeutics Class A common stock. The options are a compensation award, not an open-market purchase or sale, and give her the right to buy shares at a fixed exercise price.
What is the exercise price and expiration date of Beth Seidenberg’s Vera Therapeutics options?
The stock options have an exercise price of $34.35 per share and expire on May 20, 2036. She can choose to exercise them any time after they vest and before this expiration date, subject to the plan’s terms.
When do Beth Seidenberg’s Vera Therapeutics stock options vest?
The options vest in full on the earlier of the first anniversary of the grant date or Vera Therapeutics’ 2027 annual stockholder meeting. Vesting is conditioned on her continuous service with the company through the relevant vesting date.
What happens to Beth Seidenberg’s options if Vera Therapeutics undergoes a change in control?
If Vera Therapeutics experiences a change in control, the stock options vest in full at that time, provided Beth Seidenberg remains in continuous service through the change in control date. This accelerates vesting compared with the normal schedule.
AI-generated analysis. How Rhea-AI works. Not financial advice.
